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The in vivo administration of mAbs against T cells and T cell subsets has pro-
vided insight into the cellular mechanisms that operate in the development of
autoimmunity. Repeated injections of mAb to the L3T4 antigen has a salutary
effect on disease expression in type II collagen-induced arthritis (1), experi-
mental allergic encephalomyelitis (2), diabetes-prone NOD mice (3), and the
spontaneous systemic lupus erythematosus (SLE)-like syndromes manifested by
(NZB X NZW)F1 (4) and BXSB (5) mice. These studies have demonstrated that
the L3T4 + (CD4+) T cell subset plays a pivotal role in a variety of distinct
autoimmune diseases and suggest further that a T cell response to antigen in
the context of self class II MHC molecules, or possibly to self class II MHC
molecules alone, may be required for the induction of autoimmunity.
MRL-lpr/lpr mice also develop a lupus-like illness (6). The expression of
autoimmune features in mice that bear the lpr gene coincides with the massive
accumulation of an unusual subset of T cells, which are phenotypically Thy-1 +,
Ly-1 +, Lyt-2 - , L3T4 -, and aberrantly express the B220 antigen (7) . Neonatal
thymectomy, which abrogates lpr-dependent lymphoproliferation, prevents
autoantibody production and the development of immune-complex glomerulo-
nephritis (8, 9). Similarly, treatment of MRL-lpr/lpr mice with anti-Thy-1 .2 mAb
retards both lymphoproliferation and the progression of autoimmune disease
(10) . These observations indicate that autoimmunity in MRL-lpr/lpr mice is T
cell dependent, and have been used to implicate Thy 1', B220 + cells in the
etiopathogenesis of disease. Recently, we reported the presence of functional
abnormalities in splenic L3T4+ cells from MRL-lpr/lpr and C57BL/6-lpr/lpr
mice (11) . The current study demonstrates an important role for the L3T4 T
cell subset in the pathogenesis of IgG autoantibody production and lymphopro-
liferation in lpr-bearing mice.
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Mice.
￿
MRL mice were purchased from theJackson Laboratory, Bar Harbor, ME. The
mice were bred and maintained under conventional conditions in the animal research
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facility at the Denver Veterans Administration Medical Center, Denver, CO. Only
females were used in these studies.
Antibodies. The rat hybridomas GK1 .5 and RA3 were obtained from the American
Type Culture Collection (Rockville, MD), and D4.69 was obtained from the Human
Genetic Mutant Cell Repository (Camden, NJ). The hybridomas were grown as ascites in
sublethally irradiated, pristane-primed [C57BL/6 X DBA/2]F, mice. GK1 .5 secretes an
IgG mAb that recognizes a nonpolymorphic determinant present on L3T4+ T cells (12).
The hybridoma D4.69 (control rat Ig) produces an IgG mAb with specificity for the RT1-
N.A. antigen and shows no activity against murine cells (13). RA3 secretes an IgM mAb
that reacts with an antigen (B220) present on B cells and pre-B cells that is expressed on
the mutant T cells of lpr mice (7). Fluoresceinated anti-Thy-1 .2, anti-Lyt-2, anti-IgM, and
MAR 18.5, a murine antibody to rat K chains, were purchased from Becton Dickinson
& Co. (Mountain View, CA).
Treatment Regimens.
￿
In the first study, nine mice (4 wk old) were treated with 1 mg
of anti-L3T4 antibody given by intraperitoneal injection twice weekly. The control
groups consisted of untreated mice (n=6) and mice treated with 1 mg of control rat Ig
twice weekly (n = 8). The study was terminated 10 wk later when two mice from the anti-
L3T4-treated group became moribund coincident with administration of antibody. The
latter mice were not included in the overall analysis of results.
In a second trial, five mice (4 wk old) were treated with 1 mg of anti-L3T4 antibody
intraperitoneally per week. Control mice (n=5) received PBS. mAb injections were dis-
continued after 6 wk of therapy and the study was terminated 2 wk later.
Quantification of Antinuclear Antibodies and Total IgG in Sera.
￿
Sera were assayed for
antibodies to total histones and single-stranded DNA by an ELISA as reported earlier
(14). Antibody activity is expressed as units related to OD at 405 nm. IgG levels in sera
were also measured by ELISA, and OD values were converted to mg/ml as described
(14).
Immunofuorescence and Cytofuorographic Analyses.
￿
For direct staining, cells were incu-
bated with a previously determined optimal concentration of fluorescein-labeled mAb
(anti-Thy-1 .2, anti-Lyt-2, anti-IgM). Indirect immunofluorescence was performed by
incubating cells with mAb (anti-L3T4 or anti-B220), and then staining them with excess
purified fluorescein-conjugated MAR 18.5. Controls included cells stained with the sec-
ond-step reagent only. Fluorescence intensity was determined using an Epics C cell sorter
(Coulter Electronics Inc., Hialeah, FL) as previously reported (11).
Expression of Data.
￿
Data are expressed as the mean ± SE. Significance was deter-
mined using a nonpaired Student's t test.
Results
After 10 wk of twice weekly treatment with 1 mg of anti-L3T4, MRL-lpr/lpr
mice exhibited a marked reduction in spleen and lymph node mass (Fig. 1). The
lymph node and spleen weights in anti-L3T4-treated mice were reduced greater
than 90 and 80%, respectively, compared with control groups, and approxi-
mated those of MRL-+/+ mice. Mice treated with control rat Ig showed no
difference in the weights of lymphoid tissue compared with untreated mice.
Cells bearing the L3T4 antigen were undetectable in the spleen and lymph
nodes of anti-L3T4-treated mice (Fig. 2) . Compared with the control rat Ig-
treated mice, the percentage of B220+ T cells was also significantly decreased
after anti-L3T4 treatment. However, the residual level of these abnormal cells
remained much greater than that seen in MRL-+/+ or normal mouse strains
in which B220+ , Thy 1 + cells were undetectable (data not shown). An increase
in the percentage of Lyt-2+ cells was apparent in the anti-L3T4 group, while no
change was observed in the percentage of s1g+ or total Thy-1 .2 + cells (Fig. 2).SANTORO ET AL . BRIEF DEFINITIVE REPORT 1715
FIGURE 1 . Reduced lymphoid mass in anti-L3T4-
treated mice . Individual spleens (left panel) and
peripheral (submandibular, axillary, inguinal) lymph
nodes (right panel) were isolated from MRL-lpr/lpr
mice in the different study groups . The weights of
spleens and lymph nodes from 14-wk-old MRL-+/+
mice are shown for comparison . Spleen and lymph
node weights were significantly different (p < 0.01)
in the group that received anti-L3T4 treatment rela-
tive to those of untreated mice and mice given con-
trol Ig .
FIGURE 2 .
￿
Changes in lymphocyte subsets
after anti-L3T4 treatment. Individual
spleens and lymph nodes from mice receiv-
ing control rat Ig (open bars) or anti-L3T4
(hatched bars) were isolated and analyzed for
phenotypic composition by fluorescence
staining and cytofluorographic analyses .
The percentage of B220+sIg cells was
determined by subtracting the percentage
of sIg+ cells from that of B220 + cells . Less
than I% of cells stained positive with the
second-step reagent alone . The percent-
ages of L3T4+ cells, B220+sIg- cells, and
Lyt-2+ cells were significantly different (p
< 0.05) in the anti-L3T4 group compared
with controls.
Interestingly, the percentage of Thy-1 + cells that apparently lacked B220, Lyt-
2, and L3T4 antigens was increased after anti-L3T4 treatment relative to that
of control mice in both the spleen (23 vs . 3%) and lymph node (26 vs . 15%) .
Sera from mice treated with anti-L3T4 or control rat Ig were tested for IgG
and IgM antibodies to ssDNA and total histories (Fig . 3) . A marked reduction
in IgG antinuclear antibody levels was seen in the anti-L3T4 group . Serum IgM
anti-DNA and antihistone antibodies were, however, comparable in both groups
(Fig. 3) and significantly increased over levels in the sera of nonautoimmune
FIGURE 3 .
￿
Quantification of anti-DNA and antihistone anti-
body levels in anti-L3T4-treated mice . Sera from individual
mice given control rat Ig (open circles) or anti-L3T4 (closed
squares) were assayed for IgG autoantibodies (upper panels) or
IgM autoantibodies (lower panels). The levels of IgG anti-DNA
and IgG antihistone antibodies were significantly reduced (p <
0.001) in the anti-L3T4-treatedgroup relative to controls .171 6
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mice (data not shown). Total serum IgG levels in the anti-L3T4-treated mice
(10.1 ± 3.4 mg/ml) were similar to those in immunologically normal sex- and
age-matched (C57BL/6 X DBA/2)F, mice (7.4 ± 1 .2 mg/ml), but significantly
decreased compared with MRL-lpr/lpr mice administered control rat Ig (25 .0 ±
3 .7 mg/ml) .
Although the expression of autoimmune features was significantly reduced in
MRL-lpr/lpr mice given 2 mg of anti-L3T4 weekly, the treatment itself was
accompanied by morbidity with two of nine mice becoming moribund during
week 10 of the trial coincident with antibody administration . Although repeated
high doses of anti-L3T4 have not been reported to induce a host-immune
response to rat Ig, a reaction to foreign protein appeared to be the most likely
cause of these acute deaths . Autopsy of both mice revealed minimal lymphade-
nopathy, normal spleen weight and architecture, normal renal histology, and no
evidence of viral or bacterial infection (data not shown).
Another study using a reduced dose and shortened course of anti-L3T4 anti-
body (1 mg/wk for 6 wk) was undertaken, with control mice receiving PBS
alone. Immediately after treatment, lymphadenopathy was not clinically detect-
able in four of five antibody-treated mice. In contrast, all five untreated mice
displayed evidence of lymphoproliferation. After 6 wk of anti-L3T4 treatment,
mean levels of IgG antihistone antibodies were 0.68 ± 0 .20 U in control mice
and 0.09 ± 0 .04 U in the four anti-L3T4-treated mice without lymphadenopa-
thy. Mean IgG anti-DNA levels were 2.5 ± 0 .24 U in the untreated group and
0.85 ± 0 .18 U in the four mice that received anti-L3T4 therapy and were with-
out lymphadenopathy. The single treated mouse with lymphadenopathy had
both elevated antihistone (0.45 U) and anti-DNA (3 .8 U) antibody levels. Within
2 wk of discontinuation of anti-L3T4 treatment, all mice exhibited generalized
lymphadenopathy. Furthermore, IgG antihistone and anti-DNA antibodies rap-
idly increased to 0 .98 ± 0 .29 and 2.55 ± 0.58 U, respectively.
Discussion
The current study demonstrates for the first time that lymphoproliferation in
lpr-bearing mice, which relates mainly to the accumulation of B220+ T cells, is
heavily dependent upon the presence of the L3T4 subset. After repeated admin-
istration of anti-L3T4 antibody beginning at 4 wk old in MRL-lpr/lpr mice,
spleen and peripheral lymph node weights were reduced by greater than 80 and
90%, respectively. Moreover, a decrease in the percentage of B220+ T cells in
both spleen and lymph nodes suggests a greater than 90% total body reduction
of these mutant T cells after anti-L3T4 treatment. It is noteworthy that B220 +
T cells remained easily detectable in the treated MRL lpr/lpr mice. However,
massive expansion of this subset, which is characteristic of lpr-bearing mice (6-
8), did not occur.
We also found that anti-L3T4 treatment of MRL-lpr/lpr mice resulted in a
marked reduction in IgG anti-ssDNA and antihistone antibody production.
After 10 wk of therapy, serum levels were reduced by 85 and greater than 95%,
respectively, compared with control mice. In contrast, production of IgM anti-
bodies to these nuclear antigens appeared to be unaffected by anti-L3T4 treat-
ment. The selective dependence of IgG, but not IgM anti-DNA antibody pro-SANTORO ET AL.
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duction, on the L3T4 subset was previously reported in (NZB X NZW)F, mice
(4). The data suggest that L3T4 + T cells in both MRL-lpr/lpr and New Zealand
mice are independently involved in stimulation of autoantigen-specific B cells.
An alternative, but not mutually exclusive, explanation is that anti-L3T4 treat-
ment in MRL-lpr/lpr mice leads to decreased autoantibody production through
a reduction in the number of B220+ T cells. Whether anti-L3T4 treatment
exerted a primary or indirect effect in our study is unclear.
The L3T4 (CD4) antigen is present on T cells that primarily recognize antigen
in the context of class II MHC molecules (12). In immunologically normal mice,
there exists a subset of L3T4+ T cells that are specifically reactive to self class
II MHC antigens alone (15) . We have previously postulated a central role for
class II MHC molecules and self-reactive T cells in the etiopathogenesis of spon-
taneous murine lupus-like diseases, including that which occurs in MRL-lpr/lpr
mice (16). Hyperexpression of class II MHC antigens, which has been found on
macrophages and B cells of MRL-lpr/lpr mice and New Zealand mice (17), might
predispose to stimulation of self-reactive T cells and subsequent activation of
other lymphoid cells. This hypothesis, which predicts that treatment with either
anti-L3T4 or anti-la antibody will abrogate disease, is supported by earlier
reports in (NZB X NZW)F, mice (4, 18) and by the results presented herein in
MRL-lpr/lpr mice.
Summary
The current study examines the role of the L3T4 T cell subset in the devel-
opment of lupus-like autoimmunity and lymphoproliferation in lpr-bearing mice.
Chronic treatment of MRL-lpr/lpr mice with anti-L3T4 antibody beginning at 4
wk old was found to markedly decrease the production of IgG anti-DNA and
antihistone antibodies, while having no effect on I9M autoantibodies. A dra-
matic reduction in splenomegaly and lymphadenopathy was also observed coin-
cident with a decrease in the percentage and total number of Thy-1 +, B220+
cells. Together, the data suggest an important role for L3T4+ T cells in the
pathogenesis of disease in lpr mice and provide further evidence that a require-
ment for the L3T4 subset may be a common feature of murine autoimmunity.
The authors wish to express their appreciation to Philip Welanko for expert technical
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